

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome **BOCCADORO, MARIO**
Indirizzo **A.O.U. Città della Salute e della Scienza di Torino
Via Genova 3, 10126 Torino, Italy**
Telefono **+ 39 011 6635814**
Fax **+ 39 011 6963737**
E-mail **mario.boccardo@unito.it**
Nazionalità **Italiana**
Data di nascita **24/03/1950**

ESPERIENZA LAVORATIVA

- Date (da – a) 1975 - 1978
- Nome e indirizzo del datore di lavoro Università di Torino
- Tipo di azienda o settore Borsista
- Tipo di impiego
- Principali mansioni e responsabilità Attività di ricerca sulle caratteristiche proliferative del mieloma multiplo presso la Patologia Medica diretta dal Prof. Felice Gavosto e quindi l'Ematologia diretta dal Prof. Alessandro Pileri.

- Date (da – a) 1978
- Nome e indirizzo del datore di lavoro Departement de Biologie Moleculaire, Universite' Libre de Bruxelles, Laboratoire de Physiologie Animale, diretto dal Prof. Jaques Urbain
- Tipo di azienda o settore Borsista Fondazione Gigi Ghirotti, Borsista Euratom (Comunità Europea)
- Tipo di impiego
- Principali mansioni e responsabilità Attività di ricerca presso il Laboratorio di Immunologia per effettuare ricerche sul controllo della crescita neoplastica mediante infusione di sottopopolazioni linfocitarie in un modello murino

- Date (da – a) 1980
- Nome e indirizzo del datore di lavoro Ospedale San Giovanni Battista di Torino
- Tipo di azienda o settore Azienda Ospedaliera
- Tipo di impiego Assistente Ospedaliero presso la Divisione Universitaria di Ematologia
- Principali mansioni e responsabilità Attività clinica in reparto ed ambulatorio in ambito onco ematologico

- Date (da – a) 1982
 - Nome e indirizzo del datore di lavoro Arizona Cancer Center, Tucson, Arizona
 - Tipo di azienda o settore Università dell'Arizona
 - Tipo di impiego
- Principali mansioni e responsabilità Attività di ricerca presso Section of Hematology and Oncology" dell' Università di Tucson, Arizona in tema di mieloma multiplo

- Date (da – a) 1982
 - Nome e indirizzo del datore di lavoro Università di Torino, Dipartimento Di Medicina e Oncologia Sperimentale
 - Tipo di azienda o settore
 - Tipo di impiego Ricercatore universitario confermato
- Principali mansioni e responsabilità Attività clinica in ambito dell'onco ematologia, attività di ricerca sulle caratteristiche biologiche del mieloma multiplo, attività didattica nel corso di laurea

- Date (da – a) 1983 al presente
 - Nome e indirizzo del datore di lavoro Gruppo Italiano per lo studio del Mieloma Multiplo, Gimema Working Party
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità Coordinatore dal 1983 del Gruppo Italiano per lo studio del Mieloma Multiplo a cui partecipavano oltre 20 centri ematologici italiani per i protocolli M83 (terapia convenzionale vs polichemioterapia), M90 (terapia convenzionale vs terapia intensificata), M97 (terapia convenzionale vs autotrapianto, M2001 (trapianto convenzionale vs trapianto ad intensità ridotta). Il Gruppo dal 2007 è denominato Italian Multiple Myeloma Working Party ed attualmente coordina oltre 90 centri ematologici nazionali.

- Date (da – a) 1990
 - Nome e indirizzo del datore di lavoro Università degli Studi di Torino
 - Tipo di azienda o settore
 - Tipo di impiego Professore Ordinario di Ematologia
- Principali mansioni e responsabilità Attività clinica in ambito dell'onco ematologia, attività di ricerca sulle caratteristiche biologiche del mieloma multiplo e valutazione dell'efficacia di nuove terapie mediante trials clinici, attività didattica nel corso di laurea

- Date (da – a) 1991 - 1996
 - Nome e indirizzo del datore di lavoro European Research Network (finanziato dalla Comunità Europea, Human Capital and Mobility)
 - Tipo di azienda o settore
 - Tipo di impiego Coordinatore Italiano
- Principali mansioni e responsabilità

- Date (da – a) 2008 - 2016
 - Nome e indirizzo del datore di lavoro Azienda Ospedaliera Universitaria San Giovanni Battista di Torino
 - Tipo di azienda o settore
 - Tipo di impiego Direttore del Dipartimento di Oncologia ed Ematologia
- Principali mansioni e responsabilità Il Dipartimento include 12 strutture complesse, 11 Strutture Semplici a valenza Dipartimentale per un totale di circa 110 medici, 240 infermieri e 30 personale amministrativo. Le spese del Dipartimento ammontano a circa 80 milioni di euro.

- Date (da – a) Gennaio 2000
- Nome e indirizzo del datore di lavoro Azienda Ospedaliera Universitaria San Giovanni Battista di Torino
- Tipo di azienda o settore
- Tipo di impiego Direttore della Divisione dei Ematologia dell'Università di Torino
- Principali mansioni e responsabilità La Divisione di Ematologia dispone di 14 posti letto di degenza ordinaria, un centro di trapianto di midollo con 5 letti di degenza, 15 letti di Day Hospital, ambulatori, un laboratorio di diagnostica citofluorimetrica e molecolare, un centro interdipartimentale di criopreservazione di midollo

ISTRUZIONE E FORMAZIONE

- Date (da – a) 1975
- Nome e tipo di istituto di istruzione o formazione Università degli Studi di Torino
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita Laurea in Medicina e Chirurgia, 110/110 e lode
- Date (da – a) 1978
- Nome e tipo di istituto di istruzione o formazione Università di Bologna
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita Specializzazione in Ematologia, 70/70 e lode
- Date (da – a) 1983
- Nome e tipo di istituto di istruzione o formazione Università di Torino
- Principali materie / abilità professionali oggetto dello studio
- Qualifica conseguita Specializzazione in Medicina Interna, 70/70 e lode

Società Scientifiche:

Società Italiana di Ematologia (SIE) (consigliere del Direttivo, dal 1999)
 Società Italiana di Ematologia Sperimentale (SIES)
 American Society of Hematology (ASH)
 American Society of Clinical Oncology (ASCO)

Finanziamenti:

CNR, Progetto Ponte
 Associazione Italiana Ricerca Cancro (AIRC)
 Università di Torino (ex 60%)
 MURST (ex 40%)
 Fondazione San Paolo di Torino

Interessi scientifici:

Onco-ematologia ed in particolare il Mieloma multiplo:

- Effetto di alte dosi verso la terapia convenzionale
- Ruolo dei fattori prognostici
- Immunosorveglianza ed immunoterapia
- Alterazioni molecolari e malattia minima residua
- Nuovi farmaci nel mieloma

Oltre 290 lavori pubblicati su riviste estere con "peer reviewers. E' citato dalla "Top Italian Scientists della VIA-Academy" che include solo ricercatori con h-index>30 come riportato al link:

http://www.topitalianscientists.org/top_italian_scientists_VIA-Academy.aspx?Cerca=boccardoro

Rank	Academic	H-index	Nation	Area	Italian_Institution
64	Mario Boccardoro	72	Italy	haematology - medicine	Torino

PRIMA LINGUA ITALIANO

ALTRE LINGUE

FRANCESE
INGLESE

- | | |
|---------------------------------|--------|
| Capacità di lettura | ottima |
| • Capacità di scrittura | ottima |
| • Capacità di espressione orale | ottima |

CAPACITÀ E COMPETENZE
RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

CAPACITÀ E COMPETENZE
ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

CAPACITÀ E COMPETENZE TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc. utilizzo dei comuni mezzi informatici (Microsoft Office, Excel, Powerpoint e Browser per posta elettronica) e delle comuni apparecchiature di laboratorio (microscopio, microscopio a fluorescenza, contaglobuli, spettrofotometro)

PATENTE O PATENTI

Patente di guida C e motoveicoli, Patente nautica per imbarcazioni a vela e motore oltre le 12 miglia, brevetto di 2° grado per attività subacquea

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03



Mario Boccadoro

Pubblicazioni Scientifiche con Peer Reviewer dal 2005 (PubMed)

- Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci A, Astolfi M, Compagno M, Mariani S, Godio L, Marino L, Ruggeri M, Omede P, Palumbo A, Boccadoro M. [Cyclooxygenase-2 \(COX-2\) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.](#) Blood. 105, 4784-4791, 2005.
- Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M, Massaia M. [Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.](#) Leukemia 19, 664-670, 2005.
- Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, Coscia M, Bruno B, Boccadoro M, Massaia M. [Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells.](#) Eur J Immunol. 35, 1155-1163, 2005.
- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. [International staging system for multiple myeloma.](#) J Clin Oncol. 23, 3412-3420.
- Boccadoro M, Morgan G, Cavenagh J. [Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.](#) Cancer Cell Int. 5, 18, 2005.
- Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; [Assessment of Proteasome Inhibition for Extending Remissions \(APEX\) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.](#) N Engl J Med. 352, 2487-2498, 2005.
- Compagno M, Mantoan B, Astolfi M, Boccadoro M, Ladetto M. [Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.](#) Methods Mol Med. 113, 145-163, 2005.
- Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M. [Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.](#) Leukemia. 19, 1729-1738, 2005.
- Palumbo A, Petrucci MT, Lauta VM, Musto P, Caravita T, Barbui AM, Nunzi M, Boccadoro M; Italian Multiple Myeloma Study Group. [Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study.](#) Haematologica. 90, 858-860.
- Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, Sala AL, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'olio M, Bodenizza C, Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A. [Bortezomib \(Velcade\) for progressive myeloma after autologous stem cell transplantation and thalidomide.](#) Leukemia Res. 30, 283-285, 2006.
- Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C, Boccadoro M. [Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.](#) Cancer. 104, 1428-1433, 2005.

- Boccadoro M, Blade J, Attal M, Palumbo A. [The future role of thalidomide in multiple myeloma](#). Acta Haematol. 114, 18-22, 2005.
- Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M. [Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant](#). Eur J Haematol. 75, 391-395, 2005.
- San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. [A practical update on the use of bortezomib in the management of multiple myeloma](#). Oncologist 11, 51-61, 2006.
- Bruno B, Sorasio R, Barozzi P, Vieira J, Omedè P, Giaretta F, Rotta M, Giaccone L, Massaia M, Luppi M, Boccadoro M. [Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-mieloablative allogeneic haematopoietic transplantation](#). Eur J Haematol 76(4):342-7, 2006.
- Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M. [Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma](#). Eur J Haematol 76(4):273-7, 2006.
- Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network, GIMEMA. [Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial](#). Lancet .367(9513):825-31, 2006.
- Garino E, Berrino M, Bertinetto F, Caropreso P, Chidichimo R, Dametto E, Fasano ME, Frisaldi E, Mazzola G, Tondat F, Boccadoro M, Bruno B, Amoroso A. [Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques](#). Tissue Antigens, 67(5):427-9, 2006.
- Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P; Gruppo Italiano Trapianti di Midollo. [Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation](#). Haematologica, 91(6):837-9, 2006.
- Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, Campa E, Perfetti P, Fumagalli M, Boccadoro M. [Corticosteroids can reverse severe imatinib-induced hepatotoxicity](#). Haematologica, 91(6 Suppl):ECR27, 2006.
- Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M. [Intermediate-dose melphalan \(100 mg/m2\)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma](#). Clin Lymphoma Myeloma, 6(6):475-7, 2006.
- Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. [Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies](#). Nat Clin Pract Oncol, 3(7):374-87, 2006.
- Trojan A, Tinguely M, Vallet S, Seifert B, Jenni B, Zippelius A, Witzens-Harig M, Mechttersheimer G, Ho A, Goldschmidt H, Jäger D, Boccadoro M, Ladetto M. [Clinical significance of cyclooxygenase-2 \(COX-2\) in multiple myeloma](#). Swiss Med Wkly, 136(25-26):400-3, 2006.
- Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network, Gimema. [Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide](#). J Thromb Haemost., 4(8):1842-5, 2006.
- Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. [Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial](#). Leukemia. 20(10):1840-7, 2006.

- Majolino I, Ladetto M, Locasciulli A, Drandi D, Benedetti F, Gallamini A, Chisesi T, De Blasio A, Boccadoro M, Tarella C. [High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia's High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission](#). *Med Oncol*, 23(3):359-68, 2006.
- Conrotto D, Carrozzo M, Ubertalli AV, Gandolfo S, Giaccone L, Boccadoro M, Bruno B. [Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease](#). *Transplantation*, 82(8):1113-5, 2006.
- Bringhen S, Avonto I, Magarotto V, Boccadoro M, Palumbo A. [Investigational treatments for multiple myeloma](#). *Expert Opin Investig Drugs*, 15(12):1565-82, 2006.
- Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, Vallet S, Ricca I, Dell' Aquila M, Pagliano G, Monitillo L, Pollio B, Santo L, Cristiano C, Rocci A, Francese R, Bodoni CL, Borchiellini A, Schinco P, Boccadoro M, Tarella C. [Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements \(NLABR\) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations](#). *Exp Hematol*, 34(12):1680-6, 2006.
- Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, Astolfi M, Matteucci P, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C. [Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma](#). *Biol Blood Marrow Transplant*, 12(12):1270-6, 2006.
- Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologiche dell'Adulto. [Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma](#). *Blood*, 109(7):2767-72, 2007.
- Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P. [Management of multiple myeloma with bortezomib: experts review the data and debate the issues](#). *Oncology*, 70(6):474-82, 2006. Epub 2007.
- Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A. [Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma](#). *Eur J Haematol*, 78(4):297-302. Epub 2007.
- Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M. [Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients](#). *Leukemia*, 21(4):697-705. Epub 2007.
- Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimè R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo. [Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma](#). *Eur J Haematol*, 78(4):330-7. Epub 2007.
- Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omedè P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M. [A comparison of allografting with autografting for newly diagnosed myeloma](#). *N Engl J Med*, 356(11):1110-20, 2007.
- Rocci A, Ricca I, Dellacasa C, Longoni P, Compagno M, Francese R, Lobetti Bodoni C, Manzini P, Caracciolo D, Boccadoro M, Ferrero D, Ladetto M, Carlo-Stella C, Tarella C. [Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir](#). *Exp Hematol*, 35(4):673-81, 2007.
- Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J, Carnevale-Schianca F, Petrucci MT, Milone G, Guidi S, Rotta M, Fanin R, Corradini P, Boccadoro M, Bruno B. [Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment](#). *Biol Blood Marrow Transplant*, 13(4):497-9, 2007.
- Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M. [Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid](#). *Blood*, 110(3):921-7. Epub 2007.

- Cavallo F, Ambrosini MT, Rus C, Boccadoro M, Palumbo A. [The treatment of the elderly multiple myeloma patients](#). *Leuk Lymphoma*, 48(3):469-80, 2007.
- Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi. [Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL \(Gruppo Italiano Terapie Innovative nei Linfomi\)](#). *Leukemia*, 21(8):1802-11. Epub 2007.
- Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M. [Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy](#). *Cancer*, 110(4):824-9, 2007.
- Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, Palumbo A. [Melphalan and its role in the management of patients with multiple myeloma](#). *Expert Rev Anticancer Ther*, 7(7):945-57, 2007.
- Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. [Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial](#). *Blood*, 110(10):3557-60. Epub 2007.
- Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC. [MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts](#). *Blood*, 110(10):3744-52. Epub 2007.
- Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network. [Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network](#). *J Clin Oncol*, 25(28):4459-65. Epub 2007.
- Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G, Coscia M, Boccadoro M, Massaia M. [Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma](#). *Clin Cancer Res*, 13(18 Pt 1):5348-54, 2007.
- Palumbo A, Boccadoro M. [A new standard of care for elderly patients with myeloma](#). *Lancet*, 370(9594):1191-2, 2007.
- Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orłowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. [Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma](#). *Leukemia*, 22(2):414-23, 2008. Epub 2007.
- San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC. [Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study](#). *Leukemia*, 22(4):842-9. Epub 2008. **IF: 9.561**
- Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Scalabrini DR, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Interggruppo Italiano Linfomi (IIL). [Prospective, multicenter randomized GITMO/IIL trial comparing intensive \(R-HDS\) versus conventional \(CHOP-R\) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage](#). *Blood*, 111(8):4004-13. Epub 2008. **IF: 9.898**

- Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL. [Thalidomide for treatment of multiple myeloma: 10 years later.](#) Blood, 111(8):3968-77. Epub 2008. **IF: 9.898**
- Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. [Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.](#) Blood, 111(8):4039-47. Epub 2008. **IF: 9.898**
- Sonneveld P, Hajek R, Nagler A, Spencer A, Bladè J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators. [Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.](#) Cancer., 112(7):1529-37, 2008. **IF: 4.771**
- Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, Caravita T, Morabito F, Magarotto V, Ruggeri M, Avonto I, Musto P, Cascavilla N, Bruno B, Boccadoro M. [Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.](#) Ann Oncol 19(6):1160-5. Epub 2008 **IF: 6.425**
- Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. [Thalidomide and lenalidomide: Mechanism-based potential drug combinations.](#) Leuk Lymphom, 49(7):1238-45, 2008. **IF: 2.580**
- Cavallo F, Boccadoro M, Palumbo A. [Review of thalidomide in the treatment of newly diagnosed multiple myeloma.](#) Ther Clin Risk Manag, 3(4):543-552, 2008.
- Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A. [Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey.](#) J Clin Oncol, 26(19):3166-75. Epub 2008. **IF: 18.372**
- Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marengo P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). [WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo \(GITMO\).](#) Blood, 112(3):895-902. Epub 2008. **IF: 9.898**
- Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M. [Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.](#) Blood, 15;112(8):3107-14. Epub 2008. **IF: 9.898**
- Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giral S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group. [The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.](#) Erratum in: Leukemia, 22(8):1649, 2008. **IF: 9.561**
- Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A. [Lenalidomide and its role in the management of multiple myeloma.](#) Expert Rev Anticancer Ther, 8(6):865-74, 2008. **IF: 2.652**
- Larocca A, Cavallo F, Magarotto V, Rossi D, Patriarca F, Boccadoro M, Palumbo A. [Defibrotide: a review on clinical use and future development.](#) Expert Opin Biol Ther, 8(8):1201-12, 2008. **IF: 3.505**
- Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzone V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A; GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. [A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.](#) Cancer, 113(7):1588-95,2008. **IF: 4.771**

- Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM. [MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis](#). Proc Natl Acad Sci U S A, 105(35):12885-90. Epub 2008. **IF: 9.681**
- San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators. [Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma](#). N Engl J Med, 359(9):906-17, 2008. **IF: 53.298**
- Palumbo A, Magarotto V, Gay F, Falco P, Bringhen S, Boccadoro M. [Update on recent developments for patients with newly diagnosed multiple myeloma](#). Ann N Y Acad Sci, 1138:19-21, 2008. **IF: 3.155**
- Musto P, D'Auria F, Pietrantonio G, Bringhen S, Morabito F, Di Raimondo F, Pozzi S, Sacchi S, Boccadoro M, Palumbo A; Gruppo Italiano Malattie Ematologiche dell'Adulto Multiple Myeloma Working Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi. [Role of thalidomide in previously untreated patients with multiple myeloma](#). Expert Rev Anticancer Ther, 8(10):1569-80, 2008. **IF: 2.652**
- Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A. [Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts](#). Eur J Haematol, 2008. **IF: 2.614**
- Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG. [International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders](#). Leukemia, 2008. **IF: 9.561**
- Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. [Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates](#). Leuk Lymphoma 49(11):2156-62, 2008. **IF: 2.580**
- Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M, Anderson KC, Iacobelli M, Richardson PG. [Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias](#). Clin Cancer Res. 15(4):1210-21, 2009. **IF: 7.742**
- Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P. [The hematopoietic cell transplantation comorbidity index \(HCT-CI\) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation](#). Leukemia. 23(6):1131-8, 2009. **IF: 9.561**
- Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. [Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline](#). Br J Haematol. 144(6):895-903, 2009. **IF: 4.941**
- Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. [Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo](#). Blood. 113(14):3375-82, 2009. **IF: 9.898**
- Ferrero D, Darbesio A, Giai V, Genuardi M, Dellacasa CM, Sorasio R, Bertini M, Boccadoro M. [Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes](#). Br J Haematol. 144(3):342-9, 2009. **IF: 4.941**
- Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De Paoli L, Bergui L, Boi M, Omedè P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M. [Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia](#). Leukemia. 23(6):1062-72, 2009. **IF: 9.561**

- Bruno B, Giaccone L, Sorasio R, Boccadoro M. [Role of allogeneic stem cell transplantation in multiple myeloma](#). Semin Hematol. 46(2):158-65, 2009. . IF: **3.989**
- Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F, Larocca A, Magarotto V, Gozzetti A, Luraschi A, Morabito F, Nozza A, Knight RD, Zeldis JB, Boccadoro M, Petrucci MT. [Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results](#). Clin Lymphoma Myeloma. 9(2):145-50, 2009. IF: **1.13**
- Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P; European Myeloma Network. [The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network](#). Ann Oncol. 20(8):1303-17, 2009. IF: **6.425**
- Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Brinchen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S; IMWG. [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](#). Leukemia. 23(10):1716-30, 2009. IF: **9.561**
- Giarin MM, Giaccone L, Sorasio R, Sfiligoi C, Amoroso B, Cavallo F, Cipriani A, Palumbo A, Boccadoro M. [Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma](#). Clin Chem. 55(8):1510-6, 2009. IF: **7.905**
- Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG. [International myeloma working group \(IMWG\) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor \(AMD 3100\)](#). Leukemia. 23(10):1904-12, 2009. IF: **9.561**
- Musto P, D'Auria F, Pietrantonio G, Baldini L, Brinchen S, Caravita T, Di Raimondo F, Morabito F, Offidani M, Petrucci MT, Tosi P, Gay F, Cavo M, Boccadoro M, Palumbo A. [First-line treatment of multiple myeloma in elderly patients: the GIMEMA \(Gruppo Italiano Malattie EMatologiche dell'Adulto\) multiple myeloma working party perspective](#). Curr Drug Targets. 10(10):906-22, 2009. IF: **3.553**
- Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. [Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway](#). J Cell Mol Med. 14(12):2803-15. doi: 10.1111/j.1582-4934.2009.00926.x, 2010. IF: **4.125**
- Ruella M, Rocci A, Ricca I, Carniti C, Bodoni CL, Ladetto M, Caracciolo D, Boccadoro M, Carlo-Stella C, Corradini P, Tarella C. [Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status](#). Bone Marrow Transplant. 45(3):505-12, 2010. IF: **3.746**
- Morabito F, Gentile M, Ciulli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Brinchen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M. [Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA](#). Eur J Haematol. 84(3):223-8, 2010. IF: **2.614**
- Palumbo A, Brinchen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M. [Melphalan 200 mg/m\(2\) versus melphalan 100 mg/m\(2\) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study](#). Blood. 115(10):1873-9, 2010. Erratum in: Blood. 2010 Sep 23;116(12):2195. IF: **9.898**

- Bruno B, Giaccone L, Festuccia M, Boccadoro M. [Role of allogeneic transplantation in multiple myeloma in the era of new drugs](#). *Mediterr J Hematol Infect Dis*. 2(2):e2010013, 2010.
- Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. [Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients](#). *J Clin Oncol*. 28(5):800-7, 2010. Erratum in: *J Clin Oncol*. 28(13):2314, 2010. **IF: 18.372**
- Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA. [Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial](#). *Haematologica*. 95(7):1144-9, 2010. **IF: 6.424**
- Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A. [Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation](#). *Biol Blood Marrow Transplant*. 16(6):809-17, 2010. **IF: 3.873**
- Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. [Current multiple myeloma treatment strategies with novel agents: a European perspective](#). *Oncologist*. 15(1):6-25, 2010. **IF: 3.91**
- Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N. [AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition](#). *Oncogene*. 29(16):2325-36, 2010. **IF: 6.373**
- Crisà E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M, Ferrero D. [A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs](#). *Ann Hematol*. 89(7):691-9, 2010. **IF: 2.615**
- Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK, Durie B. [Survival and years of life lost in different age cohorts of patients with multiple myeloma](#). *J Clin Oncol*. 28(9):1599-605, 2010. **IF: 18.372**
- Lobetti-Bodoni C, Bernocco E, Genuardi E, Boccadoro M, Ladetto M. [Telomeres and telomerase in normal and malignant B-cells](#). *Hematol Oncol*. 28(4):157-67. doi: 10.1002/hon.937, 2010. **IF: 2.475**
- Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A. [Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma](#). *J Clin Oncol*. 28(12):2077-84, 2010. **IF: 18.372**
- Palumbo A, Larocca A, Falco P, Sanpaolo G, Falcone AP, Federico V, Canepa L, Crugnola M, Genuardi M, Magarotto V, Petrucci MT, Boccadoro M. [Lenalidomide, melphalan, prednisone and thalidomide \(RMPT\) for relapsed/refractory multiple myeloma](#). *Leukemia*. 24(5):1037-42, 2010. **IF: 9.561**
- Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. [Monoclonal gammopathy of undetermined significance \(MGUS\) and smoldering \(asymptomatic\) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management](#). *Leukemia*. 24(6):1121-7, 2010. **IF: 9.561**

- Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A. [Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.](#) Eur J Haematol. 85(3):200-8, 2010. . IF: **2.614**
- Offidani M, Leoni P, Bringhen S, Corvatta L, Larocca A, Gentili S, Oliva S, Polloni C, Galieni P, Catarini M, Alesiani F, Mele A, Brunori M, Blasi N, Ferranti M, Visani G, Boccadoro M, Palumbo A. [Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.](#) Leuk Lymphoma. 51(8):1444-9, 2010. IF: **2.580**
- Engelhardt M, Kleber M, Udi J, Wäsch R, Spencer A, Patriarca F, Knop S, Bruno B, Gramatzki M, Morabito F, Kropff M, Neri A, Sezer O, Hajek R, Bunjes D, Boccadoro M, Straka C, Cavo M, Polliack A, Einsele H, Palumbo A. [Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.](#) Leuk Lymphoma. 51(8):1424-43, 2010. IF: **2.580**
- Squadrone V, Massaia M, Bruno B, Marmont F, Falda M, Bagna C, Bertone S, Filippini C, Slutsky AS, Vitolo U, Boccadoro M, Ranieri VM. [Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy.](#) Intensive Care Med. 36(10):1666-74, 2010. IF: **5.399**
- Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. [European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.](#) Leuk Lymphoma. 51(11):2006-11, 2010. IF: **2.580**
- Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A. [Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.](#) Blood. 116(23):4745-53. Epub 2010 Aug 31, 2010. IF: **9.898**
- Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. [Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.](#) J Clin Oncol 28(34):5101-9, 2010. IF: **18.372**
- Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, Palumbo A. [The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.](#) Cancer. 2010 Nov 18. [Epub ahead of print] IF: **4.771**
- Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A. [Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.](#) Blood. 117(11):3025-31, 2011. IF: **9.898**
- Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. [Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.](#) J Clin Oncol. 29(8):986-93, 2011. IF: **18.372**
- Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giral S, Munshi NC, Jagannath S; International Myeloma Workshop Consensus Panel 3. [Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.](#) Blood. 117(18):4701-5, 2011. IF: **9.898**

- Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, Descamps G, Facon T, Boccadoro M, Mignard D, Harousseau JL. [Phase I study of the anti insulin-like growth factor 1 receptor \(IGF-1R\) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma](#). *Leukemia*. 25(5):872-4, 2011. **IF: 9.561**
- Guglielmelli T, Bringhen S, Roodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A. [Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients](#). *Eur J Cancer*. 47(6):814-8, 2011. **IF: 5.536**
- Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. [IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells](#). *Leukemia*. 25(5):828-37, 2011. **IF: 9.561**
- Gascón P, Aapro M, Ludwig H, Rosencher N, Boccadoro M, Turner M, MacDonald K, Muenzberg M, Abraham I. [Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments](#). *Crit Rev Oncol Hematol*. 77(3):198-200, 2011. **IF: 4.411**
- Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International Myeloma Working Group. [International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation](#). *Blood*. 117(23):6063-73, 2011. **IF: 9.898**
- Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, Carnevale-Schianca F, Festuccia M, Brunello L, Omedè P, Bringhen S, Aglietta M, Levis A, Mordini N, Gallamini A, Fanin R, Massaia M, Palumbo A, Ciccone G, Storb R, Gooley TA, Boccadoro M, Bruno B. [Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma](#). *Blood*. 117(24):6721-7, 2011. **IF: 9.898**
- Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, Palumbo A. [The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens](#). *Cancer*. 117(9):1884-90. doi: 10.1002/cncr.25743, 2011. **IF: 4.771**
- Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, Cascavilla N, Montefusco V, Lupo B, Liberati AM, Crippa C, Rossini F, Passera R, Patriarca F, Cafro AM, Omedè P, Carella AM, Peccatori J, Catalano L, Caravita T, Musto P, Petrucci MT, Boccadoro M, Palumbo A. [Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy](#). *Leukemia*. 25(10):1627-31. doi: 10.1038/leu.2011.131, 2011. **IF: 9.561**
- Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P, Bringhen S, Offidani M, Omedè P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M, Palumbo A. [Primary plasma cell leukemia in the era of new drugs: Has something changed?](#) *Crit Rev Oncol Hematol*. 2011 Jun 28. [Epub ahead of print] **IF: 4.411**
- Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M, Palumbo A, Bosia A, Coscia M, Boccadoro M, Massaia M. [Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V \$\alpha\$ 9V \$\delta\$ 2 T cells, \$\alpha\beta\$ CD8+ T cells, regulatory T cells, and dendritic cells](#). *J Immunol*. 187(4):1578-90, 2011. **IF: 5.788**
- Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hájek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. [Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network \(EMN\)](#). *Blood*. 118(17):4519-29, 2011. **IF: 9.898**
- Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. [Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance \(VMPT-VT\) versus bortezomib-melphalan-prednisone \(VMP\) in untreated multiple myeloma patients with renal impairment](#). *Blood*. 118(22):5759-66, 2011. **IF: 9.898**
- Bruno B, Gay F, Boccadoro M, Palumbo A. [Management of myeloma: an Italian perspective](#). *Clin Lymphoma Myeloma Leuk*. 11 Suppl 1:S82-6, 2011. **IF: 1.880**

- Palumbo A, Bladé J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, San Miguel J. [How to Manage Neutropenia in Multiple Myeloma](#). Clin Lymphoma Myeloma Leuk. 2011 Dec 15. [Epub ahead of print] **IF: 1.880**
- Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, Ladetto M. [Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes](#). Haematologica. 2011 Dec 29. [Epub ahead of print] **IF: 6.425**
- Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giral S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. [Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study](#). Leukemia. 26(1):149-157. doi: 10.1038/leu.2011.196, 2012. **IF: 9.561**
- Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiano E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. [Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide](#). Blood. 119(4):933-9, 2012. **IF: 9.898**
- Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. [Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study](#). Leukemia. 2012 Jan;26(1):149-57. Erratum in: Leukemia. 2012 May;26(5):1153. **IF: 9.561**
- Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A. [Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma](#). Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1209-22. **IF: 3.119**
- Lobetti-Bodoni C, Ferrero D, Genuardi E, Passera R, Bernocco E, Sia D, Grignani G, Crisà E, Monitillo L, Rocci A, Drandi D, Gaii V, Zanni M, Boi M, Isaia G, Barbero D, Lunghi M, Abruzzese E, Radaelli F, Pini M, Pregno P, Carlo-Stella C, Gaidano G, Boccadoro M, Ladetto M. [Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment](#). Mech Ageing Dev. 2012 Jul;133(7):479-88. **IF: 3.439**
- Ludwig H, Avet-Loiseau H, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Hess U, Mellqvist UH, Moreau P, San-Miguel J, Sondergeld P, Sonneveld P, Udvardy M, Palumbo A. [European perspective on multiple myeloma treatment strategies: update following recent congresses](#). Oncologist. 2012;17(5):592-606. Epub 2012 May 9. Review. Erratum in: Oncologist. 2012;17(7) **IF: 3.91**
- Crisà E, Foli C, Passera R, Darbesio A, Garvey KB, Boccadoro M, Ferrero D. [Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival](#). Br J Haematol. 2012 Jul;158(1):99-107. **IF: 4.941**
- Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM,

Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. [Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.](#) Blood. 2012 Jul 5;120(1):9-19. **IF: 9.898**

- Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Risitano AM, Selleri C, Levis A, Mordini N, Gallamini A, Pastano R, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B; Gruppo Italiano Trapianti di Midollo. [Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.](#) Biol Blood Marrow Transplant. 2012 Oct;18(10):1600-7. **IF: 3.873**
- Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S. SIE, SIES. [GITMO evidence-based guidelines on novel agents \(thalidomide, bortezomib, and lenalidomide\) in the treatment of multiple myeloma.](#) Ann Hematol. 2012 Jun;91(6):875-88. **IF: 2.615**
- Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, Catarini M, Alesiani F, Corvatta L, Gentili S, Caraffa P, Boccadoro M, Leoni P, Palumbo A. [Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.](#) Leuk Lymphoma. 2012 Sep;53(9):1722-7 **IF: 2.580**
- Larocca A, Cavallo F, Mina R, Boccadoro M, Palumbo A. [Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.](#) Future Oncol. 2012 Oct;8(10):1223-38. **IF: 3.163**
- Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M. [Dysfunctional V \$\alpha\$ 9V \$\delta\$ 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.](#) Blood. 2012 Oct 18;120(16):3271-9. **IF: 9.898**
- Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A. [Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.](#) Haematologica. 2013 Feb 26. [Epub ahead of print] PubMed PMID: 23445873. **IF: 6.424**
- Petrucci MT, Levi A, Bringhen S, Scotti S, Gentilini F, Russo S, Siniscalchi A, Larocca A, Grammatico S, Boccadoro M, Foà R, Palumbo A. [Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study.](#) Cancer. 2013 Mar 1 ;119(5):971-7. **IF: 4.771**
- Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omedè P, Boccadoro M, Palumbo A, Neri A. [Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.](#) Am J Hematol. 2013 Jan;88(1):16-23. **IF: 4.671**
- Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A. [Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.](#) Leukemia. 2013 Mar;27(3):695-701. **IF: 9.561**
- Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P. [Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.](#) Haematologica. 2013 Jan;98(1):87-94 **IF: 6.424**
- Petrucci MT, Levi A, Bringhen S, Scotti S, Gentilini F, Russo S, Siniscalchi A, Larocca A, Grammatico S, Boccadoro M, Foà R, Palumbo A. [Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a](#)

- [multicenter, open label phase 1/2 study](#). Cancer. 2013 Mar 1;119(5):971-7. doi: 10.1002/cncr.27820. Epub 2012 Oct 23. **IF: 4.771**
- Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A. [Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials](#). Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26. **IF: 6.424**
 - Fusco V, Galassi C, Berruti A, Ortega C, Ciuffreda L, Scoletta M, Goia F, Migliario M, Baraldi A, Boccadoro M, Loidoris A, Bertetto O. [Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley \(north-Western Italy\)](#). ISRN Oncol. 2013;2013:672027. doi: 10.1155/2013/672027. Epub 2013 Feb 27.
 - Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, Montefusco V, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, Corradini P, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B. [Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry](#). Biol Blood Marrow Transplant. 2013 Jun;19(6):940-8. doi: 10.1016/j.bbmt.2013.03.012. Epub 2013 Mar 26. **IF: 3.873**
 - Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Omede' P, Tassone P, Boccadoro M, Palumbo A, Neri A, Musto P. [Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome](#). Clin Cancer Res. 2013 Jun 15;19(12):3247-58. doi: 10.1158/1078-0432.CCR-12-3461. Epub 2013 Apr 18. **IF: 7.742**
 - Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede' P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A. [Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia](#). Clin Cancer Res. 2013 Jun 15;19(12):3130-42. doi: 10.1158/1078-0432.CCR-12-2043. Epub 2013 Apr 23. **IF: 7.742**
 - Lobetti-Bodoni C, Mantoan B, Monitillo L, Genuardi E, Drandi D, Barbero D, Bernocco E, Boccadoro M, Ladetto M. [Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma](#). Ther Adv Hematol. 2013 Jun;4(3):189-98. doi: 10.1177/2040620713480522.
 - Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Renna F, Lobetti Bodoni C, Gueli A, Passera R, Musto P, Boccadoro M, Tarella C, Ladetto M. [Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma](#). Ann Hematol. 2013 Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y. Epub 2013 Jun 5. **IF: 2.615**
 - Cerrano M, Crisà E, Pregno P, Aguzzi C, Riccomagno P, Boccadoro M, Ferrero D. [Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients](#). Am J Hematol. 2013 Oct;88(10):838-42. doi: 10.1002/ajh.23501. Epub 2013 Jul 23. **IF: 4.671**
 - Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantonio G, Boccadoro M, Corradini P, Palumbo A. [Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results](#). Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17. **IF: 9.898**
 - Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. [Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study](#). Blood. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16. **IF: 9.898**
 - Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, Gregory WM, Brioli A, Owen RG, Drayson MT, Wu P, Palumbo A, Boccadoro M, Davies FE, Morgan GJ. [The impact of response on bone-directed therapy in patients with multiple myeloma](#). Blood. 2013 Oct 24;122(17):2974-7. doi: 10.1182/blood-2013-04-498139. Epub 2013 Aug 23. **IF: 9.898**

- Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. [Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.](#) *Blood*. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. **IF: 9.898**
- Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. [Bortezomib, melphalan, prednisone \(VMP\) versus melphalan, prednisone, thalidomide \(MPT\) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.](#) *Am J Hematol*. 2013 Nov 25. doi: 10.1002/ajh.23641. [Epub ahead of print] **IF: 4.671**
- Petrucci MT, Calabrese E, Levi A, Federico V, Ceccolini M, Rizzi R, Gozzetti A, Falco P, Lazzaro C, Martelli E, Boccadoro M, Lauria F, Liso V, Cavo M, Foa R. [Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.](#) *Tumori*. 2013 Jul-Aug;99(4):e193-202. doi: 10.1700/1361.15125. **IF: 0.606**
- Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedè P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. [Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.](#) *J Clin Oncol*. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21. **IF: 18.372**
- Rocci A, Gambella M, Aschero S, Baldi I, Trusolino L, Cavallo F, Gay F, Larocca A, Magarotto V, Omedè P, Isaia G, Bertotti A, Liberati AM, Catalano L, De Rosa L, Musto P, Vallone R, Falcone A, Drandi D, Ladetto M, Comoglio PM, Boccadoro M, Palumbo A. [MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients.](#) *Br J Haematol*. 2014 Mar;164(6):841-50. doi: 10.1111/bjh.12719. Epub 2014 Jan 23. **IF: 4.941**
- Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. [European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma](#) *Haematologica*. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358. **IF: 6.424**
- Gambella M, Rocci A, Passera R, Gay F, Omedè P, Crippa C, Corradini P, Romano A, Rossi D, Ladetto M, Boccadoro M, Palumbo A. [High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.](#) *Haematologica*. 2014 Feb;99(2):e14-6. doi: 10.3324/haematol.2013.090142. **IF: 6.424**
- Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. [Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.](#) *Lancet Oncol*. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11. **IF: 22.589**
- Ferrero D, Crisà E, Marmont F, Audisio E, Frairia C, Giai V, Gatti T, Festuccia M, Bruno B, Riera L, Passera R, Boccadoro M. [Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.](#) *Hematol*. 2014 Aug;93(8):1391-400. doi: 10.1007/s00277-014-2047-7. Epub 2014 Apr 6. **IF: 5.868**
- Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A. [Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.](#) *Haematologica*. 2014 Jun;99(6):1114-22. doi: 10.3324/haematol.2013.099341. Epub 2014 Apr 24. **IF: 5.868**
- Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedè P, Gentiliini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A. [Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.](#) *Blood*. 2014 Jul 3;124(1):63-9. doi: 10.1182/blood-2014-03-563759. Epub 2014 May 22. **IF: 9.775**

- Foglietta M, Castella B, Mariani S, Coscia M, Godio L, Ferracini R, Ruggeri M, Muccio V, Omedé P, Palumbo A, Boccadoro M, Massaia M. [The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status.](#) Haematologica. 2014 Oct;99(10):1605-10. doi: 10.3324/haematol.2014.105866. Epub 2014 Jun 27. IF: **5.868**
- Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, Bringhen S, Musolino C, Baldini L, Musto P, Petrucci MT, Gaidano G, Passera R, Bruno B, Palumbo A, Boccadoro M, Omedé P. [Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.](#) Haematologica. 2014 Oct;99(10):1611-7. doi: 10.3324/haematol.2014.103853. Epub 2014 Jul 11. IF: **5.868**
- Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. [European perspective on multiple myeloma treatment strategies in 2014.](#) Oncologist. 2014 Aug;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. Epub 2014 Jul 25. Review. IF: **4.54**
- Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. [Autologous transplantation and maintenance therapy in multiple myeloma.](#) N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888. IF: **54.42**
- Festuccia M, Martino M, Ferrando F, Messina G, Moscato T, Fedele R, Boccadoro M, Giaccone L, Bruno B. [Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.](#) Expert Opin Biol Ther. 2015 Apr 12:1-16. [Epub ahead of print] IF: **3.653**
- Musto P, Simeon V, Grossi A, Gay F, Bringhen S, Larocca A, Guariglia R, Pietrantonio G, Villani O, D'Arena G, Cuomo C, Musto C, Morabito F, Petrucci MT, Offidani M, Zamagni E, Tacchetti P, Conticello C, Milone G, Palumbo A, Cavo M, Boccadoro M. [Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.](#) Stem Cell Res Ther. 2015 Apr 17;6(1):64. [Epub ahead of print] IF: **4.634**
- Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedé P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B. [Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.](#) Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6. PubMed PMID: 26437784. IF: **9.379**
- Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, Aydin S, Nicolino B, Festuccia M, Crisà E, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F. [Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia.](#) Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):96-103. doi: 10.1016/j.clml.2015.11.002. Epub 2015 Nov 22. PubMed PMID: 26711180. IF: **1.929**
- Gascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I. [Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced \(febrile\) neutropenia with biosimilar filgrastim \(the MONITOR-GCSF study\).](#) Support Care Cancer. 2016 Feb;24(2):911-25. doi: 10.1007/s00520-015-2861-z. Epub 2015 Aug 27. PubMed PMID: 26306517. IF: **2.495**
- Muccio VE, Saraci E, Gilestro M, Gattei V, Zucchetto A, Astolfi M, Ruggeri M, Marzanati E, Passera R, Palumbo A, Boccadoro M, Omedé P. Multiple myeloma: [New surface antigens for the characterization of plasma cells in the era of novel agents.](#) Cytometry B Clin Cytom. 2016 Jan;90(1):81-90. doi: 10.1002/cyto.b.21279. Epub 2015 Sep 23. PubMed PMID: 26287276. IF: **2.283**
- Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedé P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. [Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.](#) Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17. PubMed PMID: 26596670. IF: **24.725**

- Drandi D, Kubiczkoa-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. [Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR](#). J Mol Diagn. 2015 Nov;17(6):652-60. doi: 10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28. PubMed PMID: 26319783. **IF: 3.955**
- Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedè P, Riganti C, Palumbo A, Boccadoro M, Massaia M. [Anergic bone marrow V \$\gamma\$ 9V \$\delta\$ 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma](#). Oncoimmunology. 2015 May 26;4(11):e1047580. eCollection 2015 Nov. PubMed PMID: 26451323; PubMed Central PMCID: PMC4589055. **IF: 6.283**
- Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifluoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. [Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma](#). J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17. PubMed PMID: 26282661. **IF: 17.879**
- Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M. [Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells](#). Oncotarget. 2015 Oct 6;6(30):29833-46. doi: 10.18632/oncotarget.4006. PubMed PMID: 26284584; PubMed Central PMCID: PMC4745766. **IF: 6.627**
- Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M. [Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation](#). Bone Marrow Transplant. 2015 May;50(5):673-8. doi: 10.1038/bmt.2014.322. Epub 2015 Feb 2. PubMed PMID: 25642764. **IF: 3.466**
- Giaccone L, Brunello L, Festuccia M, Gilestro M, Maffini E, Ferrando F, Talamo E, Passera R, Boccadoro M, Omedè P, Bruno B. [Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma](#). Bone Marrow Transplant. 2015 Apr;50(4):511-6. doi: 10.1038/bmt.2014.319. Epub 2015 Feb 9. PubMed PMID: 25665043. **IF: 3.466**
- Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Falcone AP, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A. [Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival](#). Leukemia. 2015 Mar;29(3):689-95. doi: 10.1038/leu.2014.219. Epub 2014 Jul 16. PubMed PMID: 25027515. **IF: 9.379**
- Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N. [Stem cell transplantation in multiple myeloma and other plasma cell disorders \(report from an EBMT preceptorship meeting\)](#). Leuk Lymphoma. 2016 Jun;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. PubMed PMID: 26735310. **IF: 2.605**
- Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedè P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A. [A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma](#). Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22. PubMed PMID: 26898189. **IF: 9.379**
- Cerrano M, Crisà E, Gottardi E, Aguzzi C, Boccadoro M, Ferrero D. [Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta \(PDGFRB\)-rearranged myeloproliferative neoplasm](#). Am J Hematol. 2016 May 19. doi: 10.1002/ajh.24422. [Epub ahead of print] PubMed PMID: 27194679. **IF: 3.477**
- Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantonio G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. [Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma](#). Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4. PubMed PMID: 26729895. **IF: 9.775**

- Ferrero D, Cerrano M, Crisà E, Aguzzi C, Gai V, Boccadoro M. [How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience](#). Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13983. [Epub ahead of print] PubMed PMID: 26914729. **IF: 4.959**
- Cerrano M, Crisà E, Gai V, Boccadoro M, Ferrero D. [Anemia in the Elderly: not Always what it Seems](#). Mediterr J Hematol Infect Dis. 2016 Feb 25;8(1):e2016017. doi: 10.4084/MJHID.2016.017. eCollection 2016. PubMed PMID: 26977276; PubMed Central PMCID: PMC4771143.